Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, 3-7-1 Habikino Habikino-shi, Osaka, 583-8588 Japan.
Anticancer Res. 2012 Feb;32(2):609-13.
The current standard first-line chemotherapy for malignant pleural mesothelioma (MPM) is pemetrexed and cisplatin. However, other regimens, with or without a platinum agent, are reported to be effective in the treatment of MPM.
Patients who were diagnosed with MPM and treated with chemotherapy between January 1999 and June 2010 at the Osaka Prefectural Medical Center for Respiratory and Allergic Diseases were studied, and the outcomes of these patients were retrospectively analyzed in relation to therapy.
In total, 48 patients with MPM (42 men and 6 women) treated with chemotherapy were included in the current analysis. The median survival time (MST) and one-year survival rate in the pemetrexed-containing group were 541 days and 63.2%, respectively. The MST and one-year survival rate in the non-pemetrexed group were 516 days and 66.7%, respectively. Overall survival did not differ significantly with respect to the pemetrexed-containing regimen.
The superiority of pemetrexed-containing regimens is equivocal. Non-pemetrexed-containing regimens may be potent alternatives.
恶性胸膜间皮瘤（MPM）的当前标准一线化疗是培美曲塞和顺铂。然而，其他方案，无论是否含有铂剂，据报道在治疗 MPM 方面也很有效。
研究了 1999 年 1 月至 2010 年 6 月期间在大阪府立呼吸与过敏疾病医疗中心诊断为 MPM 并接受化疗的患者，并对这些患者的治疗结果进行了回顾性分析。
共有 48 例接受化疗的 MPM 患者（42 名男性和 6 名女性）纳入本研究。培美曲塞组的中位生存时间（MST）和一年生存率分别为 541 天和 63.2%。非培美曲塞组的 MST 和一年生存率分别为 516 天和 66.7%。培美曲塞组的总生存率无显著差异。
培美曲塞组的优势尚无定论。非培美曲塞组可能是有效的替代方案。
